Intellia Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

CEO

John M. Leonard

CEOJohn M. Leonard

Employees

403

Employees403

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2014

Founded2014

Employees

403

Employees403

NTLA Key Statistics

Market cap

1.00B

Market cap1.00B

Price-Earnings ratio

-1.73

Price-Earnings ratio-1.73

Dividend yield

—

Dividend yield—

Average volume

3.93M

Average volume3.93M

High today

$9.77

High today$9.77

Low today

$8.98

Low today$8.98

Open price

$9.04

Open price$9.04

Volume

5.21M

Volume5.21M

52 Week high

$28.18

52 Week high$28.18

52 Week low

$5.90

52 Week low$5.90

NTLA News

TipRanks 6h

Intellia Therapeutics’ ATTR-PN Trial Shows Promising Long-Term Efficacy, Justifying Buy Rating

JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $33.00. Con...

TipRanks 2d

Intellia Therapeutics Reports Positive Phase 1 Trial Results

Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market...

TipRanks 2d

Intellia Therapeutics announces two-year follow-up data from trial of nex-z

Intellia Therapeutics (NTLA) announced positive two-year follow-up data from the ongoing Phase 1 trial of investigational nexiguran ziclumeran, nex-z, for the t...

Analyst ratings

76%

of 29 ratings

Buy

75.9%

Hold

20.7%

Sell

3.4%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.